Jane Street Group, LLC Novavax Inc Call Options Transaction History

Jane Street Group, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$10.71 - $17.11 $11.4 Million - $18.3 Million	1,067,800 New	1,067,800 $13.5 Million
Q1 2022 May 17, 2022	SELL	$69.73 - $142.9 $23 Million - $47.2 Million	-330,000 Reduced 28.45%	830,000 $61.1 Million
Q4 2021 Feb 15, 2022	SELL	$134.56 - $217.97 $17.8 Million - $28.8 Million	-132,000 Reduced 10.22%	1,160,000 $166 Million
Q3 2021 Nov 16, 2021	BUY	$177.8 - $270.58 $93.9 Million - $143 Million	527,900 Added 69.09%	1,292,000 $268 Million
Q2 2021 Aug 16, 2021	BUY	$121.0 - $257.67 $16.2 Million - $34.6 Million	134,200 Added 21.3%	764,100 $162 Million
Q1 2021 May 18, 2021	BUY	$112.98 - $319.93 $13 Million - $37 Million	115,500 Added 22.45%	629,900 $114 Million
Q4 2020 Feb 17, 2021	SELL	$78.74 - $139.5 $32.4 Million - $57.3 Million	-411,000 Reduced 44.41%	514,400 $57.4 Million
Q3 2020 Nov 17, 2020	BUY	$79.44 - $178.51 $27 Million - $60.7 Million	339,900 Added 58.05%	925,400 $100 Million
Q2 2020 Aug 17, 2020	BUY	$13.86 - $83.61 $6.4 Million - $38.6 Million	461,700 Added 372.94%	585,500 $48.8 Million
Q1 2020 May 15, 2020	BUY	$3.93 - $16.0 $486,534 - $1.98 Million	123,800 New	123,800 $1.68 Million

291

93.3M

6.95M

9.4M

Ticker NVAX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,215,104
Market Cap $573M
Description
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Jane Street Group, LLC with notifications on news.